Visudyne

Base Information

• Chemical Name: Visudyne
• CAS No.: 129497-78-5
• Molecular Formula: C41H42N4O8
• Molecular Weight: 718.79
• Hs Code.: 2933997500
• UNII: WU713D62N9
• DSSTox Substance ID: DTXSID001031353,DTXSID30892511
• Nikkaji Number: J1.680.726E,J2.000.745A
• NCI Thesaurus Code: C76090
• RXCUI: 118886
• Metabolomics Workbench ID: 61258
• ChEMBL ID: CHEMBL2052016,CHEMBL3822934
• Mol file: 129497-78-5.mol

Synonyms:18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo(b)porphine-9,13-dipropanoic acid monomethyl ester;benzoporphyrin derivative monoacid ring A;BPD verteporfin;BPD-MA;verteporfin;verteporphin;Visudyne

Chemical Property of Visudyne

Chemical Property:

• Appearance/Colour: dark green to black solid
• PSA: 337.48000
• LogP: 10.24600
• Storage Temp.: ?20°C
• Solubility.: DMSO: soluble2mg/mL, clear (warmed)
• XLogP3: 4.9
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 10
• Rotatable Bond Count: 12
• Exact Mass: 718.30026431
• Heavy Atom Count: 53
• Complexity: 1500

Purity/Quality:

98% ^*data from raw suppliers

Verteporfin ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C
• Isomeric SMILES: CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C
• Recent ClinicalTrials: Photodynamic Therapy for the Treatment of Vertebral Metastases
• Recent EU Clinical Trials: A prospective randomized controlled multicentre trial comparing half-dose photodynamic therapy (PDT) with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (CSC).
• Description: Verteporfin was introduced in Switzerland as a second-generation photosensitizer for photodynamic therapy of wet age-related macular degeneration in patients with subfoveal choroidal neovascularisation. It is constituted of a mixture of two regioisomers resulting from nonselective monohydrolysis of the methyl tetraester. Upon irradiation with a lowenergy nonheat-generating laser light of 689nm wavelength, both regioisomeric benzoporphyrins are responsible for the local generation of singlet oxygen leading to free radical damage of neovascular endothelial cells in subfoveal lesions of patients with agerelated macular degeneration. The lipophilic drug is injected i.v. as a liposomal formulation in order to favor its uptake by plasma lipoproteins and distribution to cells with a high expression of low density lipoprotein receptors such as tumor and neovascular endothelial cells. Verteporfin is also being developed for the treatment of other eye diseases, nonmelanoma skin cancer and psoriasis. Verteporfin is a photosensitizer used during photodynamic therapy to eliminate abnormal blood vessels in the eye that are associated with conditions such as macular degeneration. It accumulates in these abnormal blood vessels and, when activated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces a highly reactive short-lived singlet oxygen and other reactive oxygen radicals, generating local damage to the endothelium and vessel occlusion. Verteporfin can also inhibit autophagosome formation by directly targeting and modifying p62, a scaffold and adaptor protein that binds both polyubiquitinated proteins destined for degradation and LC3 on autophagosomal membranes.
• Uses: Verteporfin is a photosensitizer that is used in photodynamic therapy (PDT). Verteporfin can accumulate in tumor tissues allowing for 30 to 150 minutes optimal PDT after intravenous administration. Treatment of age-related macular degeneration